South Korean drug delivery specialist InventageLab is rapidly building a global-scale manufacturing base for long-acting injectables, aiming to reach 30 million vials per year by 2028. The company's scale-out production strategy and next-generation BioFluidic platform promise to reshape supply-chain options for overseas buyers of high-concentration, room-temperature-stable injectables.
Production scale-up timeline
InventageLab plans to complete a clinical-sample production line capable of 1 million vials per year by the end of this year. By late 2025, it expects to have a commercial line producing 10 million vials annually. The final expansion to 30 million vials per year is scheduled for 2028, targeting global commercial demand from large pharmaceutical companies.
Scale-out manufacturing approach
CEO Kim Joo-hee explained that the company has already applied a technology that achieves over 10 times the production capacity per chamber compared to conventional methods. Instead of enlarging single tanks, InventageLab uses a "scale-out" model that adds parallel production modules, enabling efficient global mass production while maintaining established GMP standards.
BioFluidic platform advances
The IVL-BioFluidic platform uses microfluidics to convert intravenous biologics into subcutaneous formulations without enzymes. The technology produces dry powder particles, avoiding viscosity issues common in high-concentration liquid antibodies. InventageLab has already achieved 400 mg/mL concentration using a rituximab model and is targeting 750 mg/mL—over four times higher than current SC technologies.
What buyers should watch
Kim noted that more than one-third of recent FDA-approved drugs are high-concentration products. The BioFluidic platform reduces drug volume by over 90% compared to finished dosage forms, enabling subcutaneous injections of just 2.5–4 mL. The dry powder formulation also allows room-temperature storage and transport without cold chains, potentially lowering logistics costs for distributors and clinics.
Regulatory and channel signals
InventageLab acquired CDMO Quratis last year and secured a production base in Osong, South Korea. In March, it raised 98.5 billion KRW to expand manufacturing equipment and complete commercial GMP lines. The company is positioning itself to serve global pharma demand for long-acting injectables, a category increasingly sought after by aesthetic and therapeutic clinics for patient compliance and convenience.
Source: Read the original report | Published: June 10, 2026